Marcus Thuresson

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

Tomas Jernberg, Pål Hasvold, Martin Henriksson et al. · European Heart Journal · 2015 · 828 citations · Full text

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

Mikhail Kosiborod, Matthew A. Cavender, Alex Z. Fu et al. · Circulation · 2017 · 791 citations · Full text

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Kåre I. Birkeland, Marit E. Jørgensen, Bendix Carstensen et al. · The Lancet Diabetes & Endocrinology · 2017 · 363 citations

Metabolic Syndrome, Diabetes Management, Diabetes Epidemiology +12

Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study

Johan Sundström, Johan Bodegård, Andreas Bollmann et al. · The Lancet Regional Health - Europe · 2022 · 303 citations · Full text

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

Hiddo J.L. Heerspink, Avraham Karasik, Marcus Thuresson et al. · The Lancet Diabetes & Endocrinology · 2019 · 295 citations · Full text

Urology, Renal Disease, Real-world Clinical Practice +10